CHANGES IN THE ACTIVITY OF LIPID PEROXIDATION PROCESSES IN RATS WITH STEATOGEPATOSIS AND ITS CORRECTION WITH MYO-INOSITOL
DOI:
https://doi.org/10.11603/mcch.2410-681X.2023.i2.13970Keywords:
lipid peroxidation, antioxidant activity, inositol, steatohepatosis, ratsAbstract
Introduction. The problem of steatohepatosis or non-alcoholic fatty liver disease is currently one of the main problems of today, which burdens not only liver function, but also causes cardiovascular, neurological and renal complications. The way of correction can be the use of inositols.
The aim of the study – to evaluate the activity of the processes of lipid peroxidation in the blood of rats with steatohepatosis and to carry out correction with myo-inositol.
Research Methods. Experiments were performed on 40 white male Wistar rats. The animals were divided into 4 groups: 1 – control, 2 – steatohepatosis, 3 – myoinositol, 4 – steatohepatosis + correction with myoinositol. Steatohepatosis was induced by giving 5% glucose solution instead of drinking for 2 months. Myo-inositol powder was added to animals’ feed (porridge) for 60 days at the rate of 400 mg/kg of animal weight as inositol after simulating steatohepatosis. Superoxide dismutase and catalase activity (SOD, Cat), the content of diene and triene conjugates (DC, TC), Schiff's bases (SB) and TBA-active products were determined in blood serum.
Results and Discussion. In rats with steatohepatosis, compared to group 1, DC increased by 43.3 % (p<0.001), TC – by 43.0 % (p<0.001), TBA-active products – by 77.2 % (p<0.001), decreased SOD by 14.4 % (p<0.001) and Cat – by 14.1 % (p<0.001), and SB did not differ from control indicators. Myo-inositol at a dose of 400 mg/kg causes the accumulation of secondary products of lipid peroxidation and significant activation of antioxidants in the blood of rats, in particular, SOD – by 17.9 % (p<0.001), Cat – by 18.0 % (p<0.001). The use of myo-inositol for the treatment of formed steatogeatosis caused a decrease in DC by 14.1 % (p<0.001), TC – by 25.6 % (p<0.001), TBA-active products – by 36.1 % (p<0.001), increase of SB by 33.6 % (p<0.001), SOD – by 37.8 % (p<0.001), Cat – by 37.3 % (p<0.001). At the same time, DC were higher, compared to the control group of animals, by 23.1 % (p<0.001), TC, TBA-active products, SB, SOD and Cat did not differ from the indicators of the group of intact rats.
Conclusion. Steatohepatosis in rats causes an increase in DC, TC, TBA-active products, a decrease in SOD and Cat. Myo-inositol at a dose of 400 mg/kg causes the accumulation of secondary products of lipid peroxidation and significant activation of antioxidants in the blood of rats. In the treatment of steatohepatosis, myo-inositol at a dose of 400 mg/kg, with the normalization of eating habits, causes significantly less accumulation of lipid peroxidation products.
References
Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2018). Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol., 15, 11-20. DOI: 10.3390/nu12113379. DOI: https://doi.org/10.1038/nrgastro.2017.109
Pani, A., Giossi, R., Menichelli, D., Fittipaldo, V.A., Agnelli, F., Inglese, E., et al. F. (2020). Inositol and non-alcoholic fatty liver disease: A systematic review on deficiencies and supplementation. Nutrients, 12 (11), 3379 DOI: 10.3390/nu12113379. DOI: https://doi.org/10.3390/nu12113379
Baratta, F., Pastori, D., Angelico, F., Balla, A., Paganini, A.M., Cocomello, N., et al. (2020). Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 18, 2324-2331. DOI: 10.1016/j.cgh. 2019.12.026 DOI: https://doi.org/10.1016/j.cgh.2019.12.026
Anstee, Q.M., Mantovani, A., Tilg, H., & Targher, G. (2018). Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol., 15, 425–439. DOI: 10.1038/s41575-018-0010-0. DOI: https://doi.org/10.1038/s41575-018-0010-0
Kiani, A.K., Paolacci, S., Calogero, A.E., Cannarella, R., Di Renzo, G.C., Gerli, S., et al. (2021). From Myo-inositol to D-chiro-inositol molecular pathways. Eur. Rev. Med. Pharmacol. Sci., 25 (5), 2390-2402. DOI: 10.26355/eurrev_202103_25279.
Yuzko, O.M. (2021). Reproductive health of parents: Review of the literature. Reproductive Endocrinology, (60), 72-76. https://doi.org/10.18370/2309-4117.2021.60.72-76 [in Ukrainian]. DOI: https://doi.org/10.18370/2309-4117.2021.60.72-76
Kulik, I.I., & Khmil, S.V. (2020). The effect of sclerotherapy and pre-pregnancy training with inositol and vitamin D3 on the size and number of cysts in women with infertility on the background of endometriosis. Reports of Vinnytsia National Medical University, 24 (3), 444-448. DOI: 10.31393/reports-vnmedical-2020-24(3)-12 [in Ukrainian]. DOI: https://doi.org/10.31393/reports-vnmedical-2020-24(3)-12
Kostiuk, O.A., Denefil, O.V., & Holovata, T.K. (2018). Changes in biochemical parameters in the blood of high- and low-emotional rats with ethanol hepatosis. Medical and Clinical Chemistry. 20 (3), 125-132. DOI: 10.11603/mcch.2410-681X.2018.v0.i3.9578 [in Ukrainian]. DOI: https://doi.org/10.11603/mcch.2410-681X.2018.v0.i3.9578
Bevilacqua, A., Dragotto, J., Giuliani, A., Bizzarri, M. (2019). Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J. Cell Physiol., 234. DOI: 10.1002/jcp.27623 DOI: https://doi.org/10.1002/jcp.27623
Vlizlo, V.V. (2012). Laboratory methods of research in biology, animal husbandry and veterinary medicine: reference book. edited by V.V. Vlizlo. Lviv: SPOLOM [in Ukrainian].
Stefanova, O.V. (Ed.). (2001). Preclinical studies of medicinal products: methodical recommendations. Kyiv: Avitsenna [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
